Has Peter Mancuso, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $81,156 in general payments to Peter Mancuso, DPM across 385 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Mancuso, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Mancuso, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Mancuso, DPM

Foot & Ankle Surgery · Brentwood, NYNPI 1558339200

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,570 of the $81,156 with a category attached, or 61.1%. 41 manufacturers reported payments, led by Paratek Pharmaceuticals, Inc. at 55.1% of the total. Reporting peaked in 2022 at $23,974 and has fallen 87.6% since, to $2,962 in 2025. Among foot & ankle surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,156in general payments, 2019–2025

Across 385 payments — averaging $210.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paratek Pharmaceuticals, Inc.$45K
Medartis Inc.$13K
Merck$11K
Imbed Biosciences Inc.$3K
KCI USA, Inc.$2K
Smith+Nephew$2K
plus $7K from 35 others

What the payments were for

Consulting fees$7,0359%
Speaking & faculty fees$49,57061%
Travel & lodging$12,92516%
Food & beverage$11,62614%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paratek Pharmaceuticals, Inc.	89	$44,741
Medartis Inc.	16	$12,752
Merck	29	$11,020
Imbed Biosciences Inc.	2	$2,539
KCI USA, Inc.	16	$1,749
Smith+Nephew	69	$1,719
Baudax Bio Inc.	4	$1,259
Stryker(2 entities)	17	$935
Organogenesis Inc.	15	$573
Stability Biologics, LLC	1	$500
AbbVie(2 entities)	14	$385
Ossio Inc	2	$363
Advanced Oxygen Therapy Inc.	10	$312
Nabriva Therapeutics, PLC	15	$272
Bioventus LLC	12	$245
Integra Lifesciences Corporation	9	$212
Angiodynamics, Inc.	1	$153
Melinta Therapeutics, LLC	6	$145
Tactile Systems Technology Inc	8	$128
Kerecis Limited	3	$122
Misonix Inc	5	$117
GRT US Holding, Inc.	5	$101
Nevro Corp.	3	$75
Sebela Pharmaceuticals Inc.	4	$74
Baxter Healthcare	2	$71
Treace Medical Concepts, Inc.	3	$70
DJO, LLC	2	$64
Solventum Corporation	2	$50
Acumed LLC	1	$49
Musculoskeletal Transplant Foundation Inc.	4	$48
Zimmer Biomet	2	$40
Kowa Pharmaceuticals America, Inc.	2	$39
Paragon 28, Inc.	2	$39
Convatec Inc.	2	$39
Hartmann USA, Inc.	2	$33
Polaris Technology Solutions LLC	1	$28
Checkpoint Surgical, Inc	1	$25
Orthofix Medical, Inc.	1	$22
Lifenet Health	1	$19
Abbott	1	$17
Aroa Biosurgery Incorporated	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,156 in reported general payments places this provider in the 95th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York →

Medicare billing

Part B allowed, 2024

$607,877

Medicare patients

929

Services billed

5,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tavaborole	30	$41,147
Ketoconazole	182	$5,101
Clotrimazole	175	$3,329
Celecoxib	50	$1,270
Diclofenac Sodium	55	$1,150
Cefdinir	45	$862
Gentamicin Sulfate	15	$849
Ammonium Lactate	32	$498
Gabapentin	80	$487
Lidocaine-PrilocaineLidocaine/Prilocaine	25	$354
Terbinafine Hcl	28	$302
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip	14	$276
Doxycycline Hyclate	27	$251
Silver Sulfadiazine	22	$129
SsdSilver Sulfadiazine	14	$120

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Brentwood

James McWilliamHarrison$4.7M
Jonathan DelandNew York$4M
George Vitole Roy$2.5M
Constantine DemetracopoulosNew York$888K
Anne JohnsonNew York$815K
Scott EllisNew York$597K
John KennedyNew York$534K
Michael KellerKingston$532K
Judith BaumhauerRochester$328K
Stuart MogulNew York$131K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →